(-0.41%) 5 046.25 points
(-0.19%) 37 920 points
(-0.73%) 17 443 points
(-1.65%) $80.58
(-2.81%) $1.935
(-0.23%) $2 297.60
(0.06%) $26.67
(0.11%) $949.20
(0.01%) $0.937
(0.17%) $11.11
(0.05%) $0.801
(0.01%) $93.46
Live Chart Being Loaded With Signals
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL...
Stats | |
---|---|
Dagens volum | 40 000.00 |
Gjennomsnittsvolum | 76 857.00 |
Markedsverdi | 40.59B |
EPS | ¥0 ( 2024-02-14 ) |
Neste inntjeningsdato | ( ¥0 ) 2024-05-10 |
Last Dividend | ¥13.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 30.31 |
ATR14 | ¥0.376 (0.05%) |
Volum Korrelasjon
Seikagaku Corporation Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Seikagaku Corporation Korrelasjon - Valuta/Råvare
Seikagaku Corporation Økonomi
Annual | 2022 |
Omsetning: | ¥33.46B |
Bruttogevinst: | ¥18.02B (53.87 %) |
EPS: | ¥40.48 |
FY | 2022 |
Omsetning: | ¥33.46B |
Bruttogevinst: | ¥18.02B (53.87 %) |
EPS: | ¥40.48 |
FY | 2022 |
Omsetning: | ¥34.85B |
Bruttogevinst: | ¥20.53B (58.90 %) |
EPS: | ¥66.32 |
FY | 2021 |
Omsetning: | ¥27.66B |
Bruttogevinst: | ¥15.55B (56.21 %) |
EPS: | ¥75.54 |
Financial Reports:
No articles found.
Seikagaku Corporation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥13.00 (N/A) |
¥0 (N/A) |
¥13.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥4.44 | 2004-03-26 |
Last Dividend | ¥13.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 40 | -- |
Total Paid Out | ¥437.61 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.38 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.53 | |
Div. Directional Score | 6.61 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8174.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7552.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6762.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6101.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4812.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
4026.T | Ex Dividend Knight | 2023-10-30 | Semi-Annually | 0 | 0.00% | |
9982.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
3242.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
8966.T | Ex Dividend Knight | 2023-11-29 | Semi-Annually | 0 | 0.00% | |
2267.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0377 | 1.500 | 9.25 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0164 | 1.200 | 9.45 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0187 | 1.500 | -0.903 | -1.355 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.21 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.08 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.79 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00493 | -1.500 | 9.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 258.75 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00549 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.505 | 1.000 | 4.91 | 4.91 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0298 | 1.000 | -1.403 | -1.403 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 8.04 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.434 | 0.800 | -0.439 | -0.351 | [0.5 - 2] |
Total Score | 10.68 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 30.97 | 1.000 | 6.97 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0187 | 2.50 | -0.581 | -1.355 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.50 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -2.54 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0914 | 1.000 | -0.216 | 0 | [0.1 - 0.5] |
Total Score | 2.53 |
Seikagaku Corporation
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.